Polymorphisms of Hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapy

Intervirology

Volumn 55, Issue 1, 2011, Pages 1-11

  El Shamy, Ahmed ^a,c   Kim, Soo Ryang ^b   Ide, Yoshi Hiro ^a   Sasase, Noriko ^b   Imoto, Susumu ^b   Deng, Lin ^a   Shoji, Ikuo ^a   Hotta, Hak ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE ASAHI HOSPITAL   (Japan)

^c Suez Canal University   (Egypt)

Author keywords

Core protein; Hepatitis C virus; Interferon sensitivity determining region; Interferon ribavirin resistance determining region; Non structural protein 5A; Prediction; Sustained virological response

Indexed keywords

CORE PROTEIN; INTERFERON; NONSTRUCTURAL PROTEIN 5A; RIBAVIRIN;

ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; DISEASE ASSOCIATION; GENETIC POLYMORPHISM; HEPATITIS C VIRUS; HEREDITY; HUMAN; NONHUMAN; PRIORITY JOURNAL;

AGED; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; POLYETHYLENE GLYCOLS; POLYMORPHISM, GENETIC; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; VIRAL CORE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 80855133484     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000322219     Document Type: Article

References (30)

1. Bialek SR, Terrault NA: The changing epidemiology and natural history of hepatitis C virus infection. Clin Liver Dis 2006; 10:697-715. (Pubitemid 44880154)
2. Williams R: Global challenges in liver disease. Hepatology 2006; 44: 521-526. (Pubitemid 44433707)
3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
4. Backus LI, Boothroyd DB, Phillips BR, Mole LA: Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007; 46: 37-47. (Pubitemid 47171919)
5. Welker MW, Hofmann WP, Welsch C, von Wagner M, Herrmann E, Lengauer T, Zeu-zem S, Sarrazin C: Correlation of amino acid variations within nonstructural 4B protein with initial viral kinetics during interferon-ct-based therapy in HCV-1b-infected patients. J Viral Hepat 2007; 14:338-349. (Pubitemid 46587849)
6. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C: Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334:77-81. (Pubitemid 26017933)
7. El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H: Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated inter-feron/ribavirin combination therapy. Hepatology 2008; 48:38-47. (Pubitemid 351975529)
8. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H: Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46: 403-410. (Pubitemid 46185701)
9. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Matsuda M, Kobayashi M, Arase Y, Ikeda K, Kumada H: Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to in-terferon-ribavirin combination therapy. Intervirology 2005; 48: 372-380. (Pubitemid 41003622)
10. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, Sato K, Tsuda F, Miyakawa Y, et al: Typing hepatitis C virus by poly merase cha in react ion with t y pe-spe-cific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73: 673-679.
11. El-Shamy A, Sasayama M, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H: Prediction of efficient virological response to pe-gylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pretreat-ment sera. Microbiol Immunol 2007; 51: 471-482. (Pubitemid 46641684)
12. Ogata S, Nagano-Fujii M, Ku Y, Yoon S, Hotta H: Comparative sequence analysis of the core protein and its frameshift product, the F protein, of hepatitis C virus subtype 1b strains obtained from patients with and without hepatocellular carcinoma. J Clin Microbiol 2002; 40:3625-3630.
13. Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, Umemura T, Ichijo T, Yoshizawa K, Kiyosawa K, Tanaka E: Pretreat-ment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008; 48:1753-1760.
14. Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, Takehara T, Tanaka E, Onji M, Toyota J, Chayama K, Yoshioka K, Izumi N, Akuta N, Kumada H: Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol 2009; 44: 952-963.
15. Kau A, Vermehren J, Sarrazin C: Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008; 49:634-651.
16. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB: Genetic variation in IL28B predicts hepatitis C treatment-induced vira l clearance. Nature 2009; 461: 399-401.
17. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J: IL28B is associated with response to chronic hepatitis C interferon-a and ribavirin therapy. Nat Genet 2009; 41:1100-1104.
18. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M: Genome-wide association of IL28B with response to pegylated interferon-a and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-1109.
19. Murakami T, Enomoto N, Kurosaki M, Izumi N, Marumo F, Sato C: Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection. Hepatology 1999; 30:1045-1053. (Pubitemid 29458295)
20. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H: Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy. Intervirology 2009; 52: 301-309.
21. Tsai YH, Kuang WF, Lu TY, Kao JH, Lai MY, Liu CJ, Chen PJ, Hwang LH: The non-structural 5A protein of hepatitis C virus exhibits genotypic differences in interferon antagonism. J Hepatol 2008; 49:899-907.
22. Macdonald A, Harris M: Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 2004; 85:2485-2502. (Pubitemid 39214345)
23. Moradpour D, Evans MJ, Gosert R, Yuan Z, Blum HE, Goff SP, Lindenbach BD, Rice CM: Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J Virol 2004; 78: 7400-7409. (Pubitemid 38915885)
24. Appel N, Pietschmann T, Bartenschlager R: Mutational analysis of hepatitis C virus non-structural protein 5A: potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domain. J Virol 2005; 79: 3187-3194. (Pubitemid 40270599)
25. Yuan HJ, Jain M, Snow KK, Gale Jr M, Lee WM: Evolution of hepatitis C virus NS5A region in breakthrough patients during pe-gylated interferon and ribavirin therapy. J Viral Hepat 2009; 17: 208-216.
26. Enomoto N, Maekawa S: HCV genetic elements determining the early response to pe-ginterferon and ribavirin therapy. Intervirology 2010; 53: 66-69.
27. Hughes M, Griffin S, Harris M: Domain III of NS5A contributes to both RNA replication and assembly of hepatitis C virus particles. J Gen Virol 2009; 90: 1329-1334.
28. Appel N, Zayas M, Miller S, Krijnse-Locker J, Schaller T, Friebe P, Kallis S, Engel U, Bartenschlager R: Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. PLoS Pathog 2008; 4:e1000035.
29. Masaki T, Suzuki R, Murakami K, Aizaki H, Ishii K, Murayama A, Date T, Matsuura Y, Miyamura T, Wakita T, Suzuki T: Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J Virol 2008; 82: 7964-7976.
30. Gale M Jr, Foy EM: Evasion of intracellular host defence by hepatitis C virus. Nature 2005; 436: 939-945. (Pubitemid 41191669)